How Ashwagandha Lowers Cortisol: The HPA Axis Mechanism

Understanding the ashwagandha cortisol mechanism requires looking upstream of the adrenal gland itself. Cortisol is not a primary signal — it is the end product of a hormonal cascade that begins in the hypothalamus, proceeds through the pituitary, and terminates at the adrenal cortex. Ashwagandha's ability to lower serum cortisol appears to operate at multiple levels of this cascade, which may explain why the effect is more consistent across studies than many botanical interventions.

The Evidence Base

Ashwagandha has one of the larger human RCT records among adaptogens specifically for cortisol outcomes. Chandrasekhar et al. (2012) randomized 64 stressed adults to 300 mg/day KSM-66 ashwagandha root extract or placebo for 60 days, finding significant reductions in serum cortisol (by 27.9% versus 7.9% placebo) along with substantial reductions in PSS (Perceived Stress Scale) scores. This remains the most-cited ashwagandha cortisol study in the literature.

Clinical trials examining ashwagandha's effect on serum cortisol are summarised below.

Trial	Dose & Duration	Cortisol Reduction	Notes
Chandrasekhar et al., 2012	300 mg KSM-66 twice daily, 60 days	~27.9%	n=64 stressed adults; significant vs placebo
Auddy et al., 2008	125–250 mg Sensoril, 60 days	~14.5–24.2%	Dose-dependent reduction observed
Salve et al., 2019	240 mg KSM-66 daily, 60 days	~23%	Also improved sleep quality scores
Pratte et al., 2014	300 mg root extract, 8 weeks	Moderate reduction	Self-reported stress and fatigue improved

Langade et al. (2019) conducted a double-blind placebo-controlled trial of 300 mg twice daily KSM-66 in 58 adults with self-reported insomnia and anxiety, finding improvements in sleep quality and anxiety scores with parallel reductions in morning serum cortisol. The morning cortisol measurement is methodologically appropriate because cortisol peaks 20–30 minutes after waking (the cortisol awakening response, or CAR) and represents the best standardized measure of HPA axis activity — making it a meaningful biological endpoint rather than just a subjective outcome.

Pratte et al. (2014) conducted a systematic review of human trials of ashwagandha for anxiety, reviewing 5 eligible studies. They concluded that the evidence supported anxiolytic and cortisol-reducing effects at doses typically in the 250–600 mg/day range of standardized root extract. Wankhede et al. (2015) tested KSM-66 in resistance-trained men and found reductions in exercise-induced cortisol, suggesting the anti-stress effect extends to physiological (not just psychological) stressors.

Choudhary et al. (2017) found cognitive improvements with KSM-66, noting that cortisol reduction was a parallel finding — consistent with the known negative effects of chronically elevated cortisol on hippocampal function and working memory. Across these trials, the effect sizes for serum cortisol reduction have ranged from 15–30%, with the largest reductions in studies enrolling participants with higher baseline stress levels.

The Mechanism: HPA Axis Modulation

The hypothalamic-pituitary-adrenal (HPA) axis is the body's primary stress response system. Under stress, the hypothalamus releases corticotropin-releasing hormone (CRH), which signals the anterior pituitary to release adrenocorticotropic hormone (ACTH). ACTH travels through the bloodstream to the adrenal cortex, where it stimulates cortisol synthesis and release from zona fasciculata cells.

Under normal conditions, elevated cortisol feeds back to the hypothalamus and pituitary, suppressing CRH and ACTH release — a negative feedback loop that prevents cortisol from rising unchecked. Chronic psychological stress can impair this feedback: prolonged CRH exposure downregulates CRH receptor sensitivity, and chronic ACTH stimulation can cause adrenal hypertrophy, resulting in a hyperactive HPA axis that generates exaggerated cortisol responses to ordinary stressors.

Ashwagandha appears to restore HPA axis responsiveness through several mechanisms. Preclinical studies in rodents show that withanolide-containing extracts reduce CRH mRNA expression in the hypothalamus and lower ACTH levels in stressed animals, with corresponding reductions in corticosterone (the rodent equivalent of cortisol). The effect is stress-modulating rather than cortisol-suppressing at baseline — unstressed animals do not show the same magnitude of reduction, suggesting the mechanism involves normalizing stress hypersensitivity rather than blanket adrenal suppression.

In humans, the parallel finding is that ashwagandha's cortisol-reducing effects are largest in individuals with high baseline stress scores. This dose-response to baseline stress level is consistent with the mechanism being HPA axis normalization rather than pharmacological cortisol suppression — which would affect all users equally regardless of baseline state.

The Withanolides: Active Compounds Behind the Effect

Ashwagandha's active constituents are a class of steroidal lactones called withanolides, with withaferin A and withanolide D among the most studied. These compounds have structural similarity to glucocorticoids — they share a steroid backbone — which may partly explain their ability to interact with glucocorticoid signaling pathways.

Withaferin A has been shown in cell studies to modulate the heat shock protein HSP90, which is a chaperone for glucocorticoid receptors. By influencing HSP90 activity, withanolides may alter glucocorticoid receptor sensitivity and downstream cortisol signaling. Additionally, withanolides appear to reduce nuclear factor kappa B (NF-κB) activity, which is a transcription factor activated by both stress hormones and inflammatory cytokines — suggesting a mechanism that links stress response modulation to anti-inflammatory effects.

The withanolide content of ashwagandha root extracts varies substantially by preparation method. A standardized extract specifying withanolide content — typically 5–8% for KSM-66 — provides a more consistent and predictable dose than raw root powder, which has highly variable phytochemical content. This is the primary reason clinical trials use standardized extracts: they allow reproducible dosing of the pharmacologically active compounds. Generic ashwagandha root powder with no withanolide specification cannot be assumed to deliver the doses used in published trials.

Ashwagandha Extract Quality: Why KSM-66 Has the Trial Record

KSM-66 is a proprietary root-only extract standardized to ≥5% withanolides, using an aqueous-alcohol extraction process that preserves the full-spectrum root phytochemistry while eliminating many water-soluble compounds that contribute to GI side effects. The vast majority of published human RCTs on ashwagandha cortisol effects have used KSM-66 specifically — including Chandrasekhar et al. (2012), Langade et al. (2019), and Wankhede et al. (2015).

This matters for consumers because the evidence base is product-specific. A study showing 27.9% cortisol reduction with 300 mg KSM-66 cannot be straightforwardly applied to a product using 600 mg of unspecified root powder. The dose may be higher, but without withanolide standardization, the pharmacologically active content is unknown and likely lower per gram.

Bio:sudo KSM-66 Reishi Restore contains 600 mg KSM-66 per serving — twice the dose of the Chandrasekhar et al. trial and matching the dose used in the Langade et al. insomnia study. The 600 mg dose is also what Wankhede et al. used to demonstrate exercise-induced cortisol reduction, making it relevant for athletes managing training stress alongside psychological stress. For a broader look at how cortisol connects to your daily stress load, see How Stress Depletes Your Body.

Timing and Cortisol Rhythms

Cortisol follows a strong circadian rhythm: it peaks in the first hour after waking (the cortisol awakening response), declines throughout the morning, reaches a nadir in the evening, and rises again during early sleep before peaking at waking. Acute stress overlays this rhythm with additional pulses.

The timing of ashwagandha dosing in relation to this cortisol rhythm has not been systematically studied in RCTs — most trials used twice-daily dosing (morning and evening) without testing whether once-daily dosing at a specific time produces equivalent effects. Mechanistically, evening dosing may be particularly relevant for sleep-disrupted individuals because high evening cortisol is a primary driver of sleep onset difficulty and nocturnal waking. Langade et al. (2019) used twice-daily dosing and found improvements in both cortisol levels and sleep quality, though whether the evening dose drove the sleep benefit is not separable from the trial design.

For a broader look at the evidence for KSM-66 specifically across clinical outcomes, see KSM-66 Ashwagandha: 22 Clinical Trials.

What Ashwagandha Does Not Do

Two important clarifications about scope: First, ashwagandha reduces stress-elevated cortisol — it is not a cortisol suppressant that would impair appropriate stress responses. Individuals with properly regulated HPA axis function who take ashwagandha at therapeutic doses do not develop hypocortisolism (adrenal insufficiency). The effect is modulatory, not ablative. Second, ashwagandha does not eliminate stress — it reduces the physiological magnitude of the cortisol response to stressors that are still present. Psychological stressors require psychological management; ashwagandha reduces the neuroendocrine burden of those stressors but does not substitute for addressing them.

There are also populations for whom ashwagandha requires caution: individuals with autoimmune thyroid conditions (Hashimoto's or Graves'), pregnant women (withanolides have abortifacient activity in animal models at high doses), and those with nightshade sensitivities (ashwagandha is a member of the Solanaceae family). For a detailed look at what the RCT evidence covers, see Ashwagandha for Anxiety: A Full Review of Human Clinical Trials.

Who Benefits Most

The individuals most likely to see measurable cortisol reduction from KSM-66 ashwagandha supplementation share identifiable characteristics:

• Adults with elevated baseline stress: Chandrasekhar et al. enrolled participants specifically selected for high stress scores. Effect sizes were largest in individuals with the most dysregulated baseline cortisol.
• Individuals with sleep disruption: Langade et al. found cortisol improvements in adults with insomnia — likely because elevated evening cortisol and blunted cortisol awakening response are both normalized by HPA axis modulation.
• Athletes in high training volume periods: Wankhede et al. demonstrated cortisol reduction in resistance-trained men; exercise-induced cortisol elevation represents a genuine HPA axis load that ashwagandha can attenuate.
• Adults with persistent fatigue or HPA axis dysregulation: The subset of individuals with high perceived stress and low energy often shows a blunted cortisol awakening response — HPA axis normalization may restore circadian cortisol patterns along with energy rhythms.

Practical Takeaways

• Ashwagandha's cortisol-lowering effect operates at the HPA axis level — reducing stress-induced CRH/ACTH signaling and adrenal hyperreactivity, not suppressing adrenal function globally.
• Effect sizes in published RCTs are clinically meaningful: 15–30% reductions in serum cortisol at 300–600 mg/day KSM-66 in stressed adults.
• The active compounds are withanolides — choose products with standardized withanolide content (≥5%), not unspecified root powder.
• KSM-66 is the extract with the strongest and most replicated human trial record specifically for cortisol outcomes.
• Twice-daily dosing (morning and evening) was used in most positive trials; whether once-daily dosing is equivalent has not been established.
• Effects are strongest in individuals with genuine HPA axis dysregulation — high baseline stress, poor sleep, high training load. Less impact is expected in already-unstressed individuals.

Bottom Line

Ashwagandha's cortisol-lowering effect is among the better-characterized mechanisms in botanical supplement research: it operates via HPA axis modulation — reducing hypothalamic CRH expression, dampening ACTH-mediated adrenal activation, and normalizing cortisol rhythms in chronically stressed individuals. The human RCT evidence with KSM-66 consistently shows 15–30% reductions in serum cortisol at 300–600 mg/day. The effect is conditional on baseline stress level and is largest in individuals with clinically meaningful cortisol dysregulation. Withanolide standardization is non-negotiable — the evidence base is product-specific, and uncharacterized root powder cannot be assumed to deliver equivalent effects.

References

1. Chandrasekhar K, et al. "A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults." Indian J Psychol Med. 2012;34(3):255–262. [Source]
2. Langade D, et al. "Efficacy and safety of ashwagandha root extract in insomnia and anxiety." Medicine. 2019;98(37):e17186. [Source]
3. Wankhede S, et al. "Examining the effect of Withania somnifera supplementation on muscle strength and recovery." J Int Soc Sports Nutr. 2015;12:43. [Source]
4. Choudhary D, et al. "Efficacy and safety of ashwagandha root extract in improving memory and cognitive functions." J Dietary Suppl. 2017;14(6):599–612. [Source]
5. Pratte MA, et al. "An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha." J Altern Complement Med. 2014;20(12):901–908. [Source]

---

---